Home›Clinical trials›North Carolina

GLP-1 clinical trials in North Carolina: 30 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

30 GLP-1 clinical trials are recruiting at 65 sites in 19 cities across North Carolina. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in North Carolina

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in North Carolina

    • Atrium Health Family Medicine Research Department, Charlotte. 704-304-7176
    • Duke University Hospital, Durham. 919-668-9049

  2. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    2 sites in North Carolina

    • Revival Research Institute, LLC, Cary
    • Onsite Clinical Solutions - Huntersville, Huntersville. 800-785-3150

  3. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    1 site in North Carolina

    • Onsite Clinical Solutions, LLC - Brenner Ave, Salisbury. 800-785-3150

  4. Tirzepatide in Idiopathic Intracranial Hypertension Trial

    Phase 4. Run by Duke University. Registry number NCT07191873.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with idiopathic intracranial hypertension (IIH).

    Who can join. Adults 18 to 60, have idiopathic intracranial hypertension (IIH), BMI 30+.

    1 site in North Carolina

  5. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    6 sites in North Carolina
    • PharmQuest Life Sciences LLC, Greensboro
    • Physician's East Endocrinology, Greenville
    • Carteret Medical Group, Morehead City
    • Centricity Rsrch MHCity Multi, Morehead City
    • Piedmont Healthcare/Research, Statesville
    • Accellacare Wilmington, Wilmington

  6. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    5 sites in North Carolina

  7. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    5 sites in North Carolina
    • Research Site, Durham
    • Research Site, Morehead City
    • Research Site, Raleigh
    • Research Site, Statesville
    • Research Site, Wilmington

  8. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    3 sites in North Carolina

  9. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    3 sites in North Carolina

    • UNC Children's Hospital, Chapel Hill
    • Duke Children's Primary Care, Durham
    • Lucas Research, Inc, Morehead City. 252-222-5700

  10. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    3 sites in North Carolina

    • Duke University - Main Hospital and Clinics, Durham
    • Monroe Biomedical Research, Monroe. 704-283-7359
    • Carteret Medical Group, Morehead City. 252-499-8623

  11. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    3 sites in North Carolina

    • Centricity Research Morehead City Specialty, Morehead City
    • Accellacare of Raleigh, Raleigh
    • Accellacare Research of Wilmington, Wilmington

  12. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    3 sites in North Carolina

  13. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    2 sites in North Carolina

    • Asheville VA Medical Center, Asheville, NC, Asheville. 8282987911
    • Durham VA Medical Center, Durham, NC, Durham

  14. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in North Carolina

    • Kailera Clinical Site, Morehead City
    • Kailera Clinical Site, Morrisville

  15. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672939.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    1 site in North Carolina

    • Lucas Research, Inc., Morehead City

  16. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in North Carolina

    • Coastal Research Institute - Fayetteville, Fayetteville

  17. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in North Carolina

    • Coastal Research Institute - Fayetteville, Fayetteville

  18. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in North Carolina

  19. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    4 sites in North Carolina

  20. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    2 sites in North Carolina

    • Carteret Medical Group, Morehead City
    • Brookview Hills Research Associates, LLC, Winston-Salem
The other 10 studies recruiting in North Carolina

  1. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    2 sites in North Carolina

  2. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07415954.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    2 sites in North Carolina

    • PharmQuest, Greensboro
    • Piedmont Healthcare Statesville, Statesville

  3. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    2 sites in North Carolina

    • PharmQuest, Greensboro
    • KDCILM, LLC & Accellacare US, Inc., Wilmington

  4. Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

    Phase 2. Run by University of Colorado, Denver. Registry number NCT06975111.

    A study of a GLP-1 medicine, semaglutide, in women going through menopause.

    Who can join. Adults 45 to 55, women only, are going through menopause.

    1 site in North Carolina

    • University of North Carolina, School of Medicine, Chapel Hill. 919-908-0010

  5. PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm

    Phase 2. Run by Veru Inc. Registry number NCT07446998.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with mobility disability lose weight.

    Who can join. Adults 65+, have obesity or are overweight, BMI 35+.

    1 site in North Carolina

  6. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in North Carolina

    • KDCILM, LLC & Accellacare US, Inc., Wilmington

  7. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Run by Novo Nordisk A/S. Registry number NCT07607587.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in North Carolina

    • Monroe Biomedical Research, LLC, Monroe
    • Accellacare, Wilmington

  8. Tirzepatide in Obesity-Driven Endometrial Cancer

    Phase 1. Run by UNC Lineberger Comprehensive Cancer Center. Registry number NCT07065552.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with endometrial cancer lose weight.

    Who can join. Adults 18+, women only, have endometrial cancer, BMI 30+.

    1 site in North Carolina

    • Lineberger Comprehensive Cancer Center, Chapel Hill. 919-966-5996

  9. Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance

    Phase 1. Run by David D'Alessio, M.D. Registry number NCT07224334.

    A study in people with diabetes.

    Who can join. Adults 18 to 60, have diabetes.

    1 site in North Carolina

  10. MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

    Run by Dr. Christopher McGowan. Registry number NCT06734312.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 21 to 65, have obesity, BMI 30+.

    1 site in North Carolina

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.